# US 2022/0054617 A1 · Subunit vaccine constructs for flaviviruses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0054617 A1
- Document ID: US20220054617A1
- Status: Published application
- Kind: A1
- Application number: 17/312,534
- Filed: 2019-12-12
- Published: 2022-02-24
- Earliest claimed: 2018-12-12
- Assignees: Regents of the University of Minnesota; Kanpro Research, Inc.
- Applicants: Regents of the University of Minnesota; Kanpro Research, Inc.
- Inventors: Sunil A. David; Michael J.H. Brush; Fei Philip Gao
- Web page: https://patentgrep.com/patent/US20220054617A1

## CPC

- A61K 39/12: Viral antigens
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- G01N 33/56988: {HIV or HTLV}
- A61K 2039/55511: {Organic adjuvants}
- C12N 2770/24122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/24134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- G01N 2333/16: HIV-1, HIV-2
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This disclosure describes a subunit vaccine for a flavivirus, methods of making the vaccine, and methods of using the vaccine. The flavivirus may include, is a mosquito-borne flavivirus, for example, Zika virus (ZIKV), dengue virus (DENV), Yellow Fever (YF) virus, and West Nile Virus (WNV). The subunit vaccine may be administered with an adjuvant.

## Claims

### Claim 1

A subunit vaccine for a flavivirus, the vaccine comprising an antigen, the antigen comprising a sequence having at least 80% sequence identity to one of SEQ ID NO:1 to SEQ ID NO:12.

### Claim 2 (depends on 1)

The subunit vaccine of claim 1, wherein the antigen comprises a sequence having at least 90% sequence identity to one of SEQ ID NO:1 to SEQ ID NO:12.

### Claim at position 3

3-6. (canceled)

### Claim 7 (depends on 1)

The subunit vaccine of claim 1, wherein the flavivirus comprises at least one of Zika virus (ZIKV), dengue virus (DENV), Yellow Fever (YF) virus, and West Nile Virus (WNV).

### Claim at position 5

8-18. (canceled)

### Claim 19 (depends on 1)

A pharmaceutical composition comprising:
the subunit vaccine of claim 1, and
a pharmaceutically acceptable carrier.

### Claim 20 (depends on 19)

The composition of claim 19, the composition further comprising an adjuvant.

### Claim 21 (depends on 20)

The composition of claim 20, the adjuvant comprising hyaluronic acid.

### Claim 22 (depends on 20)

The composition of claim 20, the adjuvant comprising a TLR agonist.

### Claim 23 (depends on 22)

The composition of claim 22, the TLR agonist comprising at least one of a TLR 7 and a TLR 8 agonist.

### Claim 24 (depends on 22)

The composition of claim 22, the TLR agonist comprising [5-(3-(aminomethyl)benzyl)-3-pentylquinolin-2-amine].

### Claim 25 (depends on 20)

The composition of claim 20, the adjuvant comprising a covalent conjugate of hyaluronic acid and a TLR agonist.

### Claim 26 (depends on 20)

The composition of claim 20, the adjuvant comprising

### Claim at position 14

27-34. (canceled)

### Claim 35 (depends on 1)

A method of making the subunit vaccine of claim 1.

### Claim 36 (depends on 35)

The method of claim 35, wherein the method comprises expressing a construct comprising a sequence encoding the antigen, wherein the resulting antigen is operably linked to a tag.

### Claim 37 (depends on 35)

The method of claim 35, wherein the method comprises expressing a construct comprising the antigen and a sequence encoding a tag, wherein the construct further comprises a protease cleavage site between the sequence encoding the antigen and the sequence encoding the tag.

### Claim 38 (depends on 37)

The method of claim 37, wherein the protease cleavage site comprises a TEV protease cleavage site.

### Claim 39 (depends on 36)

The method of claim 36, wherein the tag comprises a maltose binding protein (MBP), a small ubiquitin-like modifier (SUMO), a Glutathione S-transferase (GST), a Streptococcal G protein (SGp), or combinations and/or portions thereof.

### Claim 40 (depends on 36)

The method of claim 36, wherein the tag comprises SEQ ID NO:13 or SEQ ID NO:14.

### Claim 41

(canceled)

### Claim 42 (depends on 36)

The method of claim 36, the method further comprising cleaving the tag from the antigen.

### Claim 43 (depends on 42)

The method of claim 42, wherein the tag is cleaved from the antigen by TEV protease.

### Claim 44 (depends on 1)

A method comprising administering the subunit vaccine of claim 1.

### Claim at position 25

45-60. (canceled)
